ly3200882

Small moleculeexperimental

Clinical trial activity

4 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Nov 9, 2016 (NCT02937272)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ly3200882
  • ly3200882

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04031872Phase 1/Phase 2 (Phase 2)Feb 29, 2020Agendia, Catalan Institute of Health, Eli Lilly, European Organisation for Research and Treatment of Cancer, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, INCLIVA, Katholieke Universiteit Leuven, Netherlands Cancer Institute, Universidad Autonoma de Barcelona, University of Amsterdam, University of Campania Luigi Vanvitelli, University of Turin, University of Valencia
NCT04158700Phase 1/Phase 2 (Phase 2)Dec 5, 2019Eli Lilly, Merck
NCT03792139Phase 1Jan 8, 2019Eli Lilly
NCT02937272Phase 1Nov 9, 2016Eli Lilly
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit4322016
AgendiaFor profit1012020
Catalan Institute of HealthGovernment1012020
European Organisation for Research and Treatment of CancerAcademic/Hospital1012020
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoAcademic/Hospital1012020
INCLIVAAcademic/Hospital1012020
Katholieke Universiteit LeuvenAcademic/Hospital1012020
MerckFor profit1012019
Netherlands Cancer InstituteAcademic/Hospital1112020
Universidad Autonoma de BarcelonaAcademic/Hospital1012020
University of AmsterdamAcademic/Hospital1012020
University of Campania Luigi VanvitelliAcademic/Hospital1012020
University of TurinAcademic/Hospital1012020
University of ValenciaAcademic/Hospital1012020
14 organizations
Page 1 / 1